EI
PSTX

EAM Investors’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

EAM Investors’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-218,305
Closed -$1.16M – 375
2022
Q4 		$1.16M Buy
+218,305
New +$998K 0.24% 198

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

EAM Investors's PSTX Position: Q1 2023 in Review

EAM Investors sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2023, closing a stake of 218,305 shares — an estimated $1.16M sold.

EAM Investors first reported a position in PSTX in Q4 2022 and held it in 1 quarter. The position peaked at $1.16M in Q4 2022. 101 funds tracked by Wall St. Rank hold PSTX as of Q1 2023.

  • EAM Investors reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • EAM Investors sold 218,305 Poseida Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $1.16M.
  • EAM Investors first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • EAM Investors's Poseida Therapeutics, Inc. Common Stock position peaked at $1.16M in Q4 2022.
  • 101 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2023.

Based on EAM Investors's 13F filing for Q1 2023, filed 15 May 2023.